{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-091905","form_type":"8-K","ticker":"PFSA","cik":"0001859807","company_name":"Profusa, Inc.","filed_at":"2026-08-20T12:32:30+00:00","discovered_at":"2026-08-20T12:35:00.473557+00:00","generated_at":"2026-08-20T12:35:07.501126+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Profusa Q2 net loss $8.8M; cash $719K; progress on G3 option","bullets":["Net loss Q2 2026 $(8.8)M vs $(2.2)M year-ago; six-month loss $(12.2)M vs $(5.1)M.","Cash at June 30 $719K; total assets $1.0M; stockholders' deficit $(27.1)M.","Debt/liability holders executed $10.7M Series A Convertible Exchange Agreements; $4.57M converted to preferred.","Borrowed $650K for working capital; 4:1 reverse stock split effective Aug 18, 2026.","G3 audits expected by mid-September; combined company to operate as public diagnostics with CLIA labs."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-091905","json":"https://secwatch.observer/filing/0001213900-26-091905.json","markdown":"https://secwatch.observer/filing/0001213900-26-091905.md","text":"https://secwatch.observer/filing/0001213900-26-091905.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859807/000121390026091905/0001213900-26-091905-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859807/000121390026091905/ea0302812-8k_profusa.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-20T12:35:07.501126+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}